女性抗骨质疏松药物使用与COVID-19相关结局无关联:全国队列研究
该研究基于土耳其全国多中心回顾性队列,纳入2020年3月11日至5月30日确诊COVID-19的50岁以上女性,将使用抗骨质疏松药物者与1:1倾向评分匹配的未使用者比较。结果显示治疗组与对照组住院率和死亡率相似,ICU入住率较低(23.0% vs 27.0%,p=0.013),但多因素分析显示药物使用并非任何结局的独立相关因素。结论认为既往使用抗骨质疏松药物未改变COVID-19相关住院、ICU入住和死亡风险,不建议因感染而停药。
要点
- 抗骨质疏松药物使用未改变COVID-19住院、ICU入住和死亡风险。
- ICU入住率治疗组较低但多因素分析无独立关联。
- 双膦酸盐、地舒单抗或特立帕肽使用者结局相似。
核心结论
- 女性既往使用抗骨质疏松药物未改变COVID-19相关住院、ICU入住和死亡风险。
- 结果不支持在COVID-19感染期间停用抗骨质疏松药物。
研究设计与样本
- 全国多中心回顾性队列,数据来自土耳其卫生部数据库,纳入2020年3月11日至5月30日确诊COVID-19的50岁以上女性。
- 抗骨质疏松药物使用者与1:1倾向评分匹配的未使用者比较,共分析1997对。
主要发现
- 治疗组中1787例(89.5%)使用双膦酸盐,197例(9.9%)使用地舒单抗,17例(0.9%)使用特立帕肽(近12个月)。
- 治疗组与对照组住院率和死亡率相似。
- ICU入住率治疗组较低(23.0% vs 27.0%,p=0.013),但多因素分析显示药物使用并非任何结局的独立相关因素。
- 双膦酸盐、地舒单抗或特立帕肽使用者之间住院、ICU入住和死亡率相似。
临床怎么用
- COVID-19感染期间不应仅因感染而停用抗骨质疏松药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This study was performed to evaluate whether the use of drugs in the treatment of osteoporosis in women is associated with COVID-19 outcomes. The results showed that the risk of hospitalization, intensive care unit admission, and mortality was not altered in individuals taking anti-osteoporosis drugs, suggesting no safety issues during a COVID-19 infection. INTRODUCTION: Whether patients with COVID-19 receiving anti-osteoporosis drugs have lower risk of worse outcomes has not been reported yet. The aim of this study was to evaluate the association of anti-osteoporosis drug use with COVID-19 outcomes in women. METHODS: Data obtained from a nationwide, multicenter, retrospective cohort of patients diagnosed with COVID-19 from March 11th to May 30th, 2020 was retrieved from the Turkish Ministry of Health Database. Women 50 years or older with confirmed COVID-19 who were receiving anti-osteoporosis drugs were compared with a 1:1 propensity score-matched COVID-19 positive women who were not receiving these drugs. The primary outcomes were hospitalization, ICU (intensive care unit) admission, and mortality. RESULTS: A total of 1997 women on anti-osteoporosis drugs and 1997 control patients were analyzed. In the treatment group, 1787 (89.5%) women were receiving bisphosphonates, 197 (9.9%) denosumab, and 17 (0.9%) teriparatide for the last 12 months. Hospitalization and mortality rates were similar between the treatment and control groups. ICU admission rate was lower in the treatment group (23.0% vs 27.0%, p = 0.013). However, multivariate analysis showed that anti-osteoporosis drug use was not an independent associate of any outcome. Hospitalization, ICU admission, and mortality rates were similar among bisphosphonate, denosumab, or teriparatide users. CONCLUSION: Results of this nationwide study showed that preexisting use of anti-osteoporosis drugs in women did not alter the COVID-19-related risk of hospitalization, ICU admission, and mortality. These results do not suggest discontinuation of these drugs during a COVID-19 infection.
引用
- Atmaca A, Demirci I, Haymana C, et al. No association of anti-osteoporosis drugs with COVID-19-related outcomes in women: a nationwide cohort study. Osteoporos Int. 2021. PMID: 34402949. doi:10.1007/s00198-021-06067-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。